The present study was undertaken to evaluate the effects of chronic treatment with c-AUCB {cis-4-[4-(3-adamantan-1-ylureido)cyclohexyl-oxy]benzoic acid}, a novel inhibitor of sEH (soluble epoxide hydrolase), which is responsible for the conversion of biologically active EETs (epoxyeicosatrienoic acids) into biologically inactive DHETEs (dihydroxyeicosatrienoic acids), on BP (blood pressure) and myocardial infarct size in male heterozygous TGR (Ren-2 renin transgenic rats) with established hypertension. Normotensive HanSD (Hannover Sprague-Dawley) rats served as controls. Myocardial ischaemia was induced by coronary artery occlusion. Systolic BP was measured in conscious animals by tail plethysmography. c-AUCB was administrated in drinking water. Renal and myocardial concentrations of EETs and DHETEs served as markers of internal production of epoxygenase metabolites. Chronic treatment with c-AUCB, which resulted in significant increases in the availability of biologically active epoxygenase metabolites in TGR (assessed as the ratio of EETs to DHETEs), was accompanied by a significant reduction in BP and a significantly reduced infarct size in TGR as compared with untreated TGR. The cardioprotective action of c-AUCB treatment was completely prevented by acute administration of a selective EETs antagonist [14,15-epoxyeicosa-5(Z)-enoic acid], supporting the notion that the improved cardiac ischaemic tolerance conferred by sEH inhibition is mediated by EETs actions at the cellular level. These findings indicate that chronic inhibition of sEH exhibits antihypertensive and cardioprotective actions in this transgenic model of angiotensin II-dependent hypertension.

Department of Developmental Cardiology Institute of Physiology Academy of Sciences of the Czech Republic Prague Czech Republic

Zobrazit více v PubMed

Lloyd-Jones DM. Cardiovascular risk prediction: basic concepts, current status, and future directions. Circulation. 2010;121:1768–1777. PubMed

Prisant LM. Hypertensive heart disease. J Clin Hypertens. 2005;7:231–238. PubMed PMC

Ostadal B. The past, the present and the future of experimental research on myocardial ischemia and protection. Pharmacol Rep. 2009;61:3–12. PubMed

Lavu M, Bhushan S, Lefer DJ. Hydrogen sulfide-mediated cardioprotection: mechanisms and therapeutic potential. Clin Sci. 2010;120:19–29. PubMed

Besik J, Szarszoi O, Kunes J, Netuka I, Maly J, Kolar F, Pirk J, Ostadal B. Tolerance to acute ischemia in adult male and female spontaneously hypertensive rats. Physiol Res. 2007;56:267–274. PubMed

Csonka C, Kupai K, Kocsis GF, Novak G, Fekete V, Bencsik P, Csont T, Ferdinandy P. Measurement of myocardial infarct size in preclinical studies. J Pharmacol Toxicol Methods. 2010;61:163–170. PubMed

Ferdinandy P, Schulz R, Baxter GF. Interaction of cardiovascular risk with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol Rev. 2007;59:418–458. PubMed

Maroko PR, Kjekshus JK, Sobel BE, Watanabe T, Covell JW, Ross J, Jr, Braunwald E. Factors influencing infarct size following experimental coronary artery occlusions. Circulation. 1971;43:67–82. PubMed

Nithipatikom K, Gross GJ. Epoxyeicosatrienoic acids: novel mediators of cardioprotection. J Cardiovasc Pharmacol Ther. 2010;15:112–119. PubMed

Fleming I, Busse R. Endothelium-derived epoxyeicosatrienoic acids and vascular function. Hypertension. 2006;47:629–633. PubMed

Imig JD, Hammock BD. Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat Rev Drug Discover. 2009;8:794–805. PubMed PMC

Sudhahar V, Shaws S, Imig JD. Epoxyeicosatrienoic acid analogs and vascular function. Curr Med Chem. 2010;17:1181–1190. PubMed PMC

Certikova Chabova V, Kramer HJ, Vaneckova I, Thumova M, Skaroupkova P, Tesar V, Falck JR, Imig JD, Cervenka L. The roles of intrarenal 20- hydroxyeicosatetroenoic and epoxyeicosaetraenoic acids in the regulation of renal function in hypertensive Ren-2 transgenic rats. Kidney Blood Press Res. 2007;30:335–346. PubMed

Certikova Chabova V, Walkovska A, Kompanowska-Jezierska E, Sadowski J, Kujal P, Vernerova Z, Vanourkova Z, Kopkan L, Kramer HJ, Falck JR, Imig JD, Hammock BD, Vaneckova I, Cervenka L. Combined inhibition of 20-hydroxyeicosatetrenoic acid formation and epoxyeicosaetraenoic degradation attenuates hypertension and hypertension-induced end-organ damage in Ren-2 transgenic rats. Clin Sci. 2010;118:617–632. PubMed PMC

Mullins JJ, Peters J, Ganten D. Fulminant hypertension in transgenic rats harboring the mouse Ren-2 gene. Nature. 1990;344:541–544. PubMed

Gross GJ, Gauthier KM, Moore JM, Falck JR, Hammock BD, Campbell WB, Nithipatikom K. Effects of the selective EET antagonist, 14,15-EEZE, on cardioprotection produced by exogenous or endogenous EETs in the canine heart. Am J Physiol Heart Circ Physiol. 2008;294:H2838–H2844. PubMed PMC

Gross GJ, Baker JE, Hsu A, Wu HE, Falck JR, Nithipatikom K. Evidence for a role of opioids in epoxyeicosatrienoic acid-induced cardioprotection in rat hearts. Am J Physiol Heart Circ Physiol. 2010;298:H2201–H2207. PubMed PMC

Seubert JM, Sinal CJ, Graves J, DeGraff LM, Bradbury JA, Lee CR, Goralski K, Carey MA, Luria A, Newman JW, Hamm JR, Roberts H, Rockman HA, Murphy E, Zeldin DC. Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function. Circ Res. 2006;99:442–450. PubMed PMC

Bathu SN, Lee SB, Qadhi RS, Chaudhary KR, El-Sikhry H, Kodela R, Falck JR, Seubert JM. Cardioprotective effect of a dual acting epoxyeicosatrienoic acid analoque towards ischaemia reperfusion injury. Br J Pharmacol. 2011;162:897–907. PubMed PMC

Hwang SH, Tsai HJ, Liu JY, Morisseau C, Hammock BD. Orally bioavailable potent soluble epoxide hydrolase inhibitors. J Med Chem. 2007;50:3825–3840. PubMed PMC

Honetschlagerova Z, Huskova Z, Vanourkova Z, Sporkova A, Kramer HJ, Hwang SH, Tsai HJ, Hammock BD, Imig JD, Cervenka L, Kopkan L. Renal mechanisms contributing to the antihypertensive action of soluble epoxide hydrolase inhibition in Ren-2 transgenic rats with inducible hypertension. J Physiol. 2011;589:207–219. PubMed PMC

Kujal P, Certikova Chabova V, Vernerova Z, Walkowska A, Kompanowska-Jezierska E, Vanourkova Z, Huskova Z, Opocensky M, Skaroupkova P, Schejbalova S, Kramer HJ, Rakusan D, Maly J, Netuka I, Vanecková I, Kopkan L, Cervenka L. Similar renoprotection after renin-angiotensin-dependent and –independent antihypertensive therapy in 5/6-nephrectomized Ren-2 transgenic rats: are there blood pressure-independent effects? Clin Exp Pharmacol Physiol. 2010;37:1159–1169. PubMed

Walkowska A, Skaroupkova P, Huskova Z, Vanourkova Z, Certiková Chabova V, Tesar V, Kramer HJ, Falck JR, Imig JD, Kompanowska-Jezierska E, Sadowski J, Cervenka L. Intrarenal cytochrome P-450 metabolites of arachidonic acid in the regulation of the nonclipped kidney function in two-kidney, one-clip Goldblatt hypertensive rats. J Hypertens. 2010;28:582–593. PubMed PMC

Neckar J, Papousek F, Novakova O, Ostadal B, Kolar F. Cardioprotective effects of chronic hypoxia and preconditioning are not additive. Basic Res Cardiol. 2002;97:161–167. PubMed

Curtis MJ, Walker MJ. Quantification of arrhythmias using systems: an examination of seven scores in an in vivo model of regional myocardial ischaemia. Cardiovasc Res. 1988;22:656–665. PubMed

Asemu G, Neckar J, Szarszoi O, Papousek F, Ostadal B, Kolar F. Effects of adaptation to intermittent high altitude hypoxia on ischemic ventricular arrhythmias in rats. Physiol Res. 2000;49:597–606. PubMed

Imig JD. Targeting epoxides for organ damage in hypertension. J Cardiovasc Pharmacol. 2010;56:329–335. PubMed PMC

Williams JM, Murphy S, Burke M, Roman RJ. 20-hydroxyeicosatetraenoic acid: a new target for the treatment of hypertension. J Cardiovasc Pharmacol. 2010;56:336–344. PubMed PMC

Melenovsky V, Benes J, Skaroupkova P, Sedmera D, Strnad H, Kolar M, Vlcek C, Petrak J, Benes J, Jr., Papousek F, Oliarnyk O, Kazdova L, Cervenka L. Metabolic charactrization of volume overload heart failure due to aorto-caval fistula in rats. Mol Cell Biochem. 2011;354:83–96. PubMed

Neckar J, Silhavy J, Zidek V, Landa V, Mlejnek P, Simakova M, Seidman JG, Seidman C, Kazdova L, Klevstig M, Novak F, Vecka M, Papousek F, Houstek J, Drahota Z, Kurtz TW, Kolar F, Pravenec M. CD36 overexpression predisposes to arrhythmias but reduces infarct size in spontaneously hypertensive rats: gene expression profile analysis. Physiol. Genomics. 2011 in press. PubMed PMC

Rakusan K, Cicutti N, Kolar F. Effect of anemia on cardiac function, microvascular structure, and capillary hematocrit in rat hearts. Am J Physiol Heart Circ Physiol. 2001;280:H1407–H1414. PubMed

Madhun ZT, Goldthwait DA, McKay D, Hopfer U, Douglas JG. An epoxygenase metabolite of arachidonic acid mediates angiotensin II-induced rises in cytosolic calcium in rabbit proximal tubule epithelial cells. J. Clin. Invest. 1991;88:456–461. PubMed PMC

Sakairi Y, Jacobson HR, Noland DT, Capdevila JH, Falck JR, Breyer MD. 5,6-EET inhibits ion transport in collecting duct by stimulating endogenous prostaglandin synthesis. Am J Physiol Renal Physiol. 1995;268:F931–F939. PubMed

Imig JD, Zhao X, Falck JR, Wei S, Capdevila JH. Enhanced renal microvascular reactivity to angiotensin II in hypertension is ameliorated by the sulfonimide analog of 11,12- epoxyeicosatrienoic acid. J Hypertens. 2001;19:983–992. PubMed

Cooley DA, Reul GJ, Wukasch DC. Ischemic contracture of the heart: “stone heart”. Am J Cardiol. 1972;29:575–577. PubMed

Anderson PG, Bishop SP, Dignerness SB. Transmural progression of morphological changes during ischemia and reperfusion in the normal and hypertrophied heart. Am J Pathol. 1987;129:152–167. PubMed PMC

Minor T, Isselhard W, Sturz J. Recovery of healthy and hypertrophied hearts after global ischemia and gradual reperfusion. Ann Cardiol Angeiol. 1994;43:395–399. PubMed

Snoeckx LH, van der Vusse GJ, Coumans WA, Willemsen PH, van der Nagel T, Reneman RS. Myocardial function in normal and spontaneously hypertensive rats during reperfusion after a period of global ischaemia. Cardiovasc Res. 1986;20:67–75. PubMed

Mozaffari MS, Schaffer SW. Effect of hypertension and hypertension-glucose intolerance on myocardial ischemic injury. Hypertension. 2003;42:1042–1049. PubMed

Saupe KW, Lim CC, Ingwall JS, Apstein CS, Eberli FR. Comparision of hearts with 2 types of pressure-overload left ventricular hypertrophy. Hypertension. 2000;35:1167–1172. PubMed

Chaudhary KR, Abukhashim M, Hwang SH, Hammock BD, Seubert JM. Inhibition of soluble epoxide hydrolase by trans-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyl-oxy]-benzoic acid is protective against ischemia-reperfusion injury. J Cardiovasc Pharmacol. 2010;55:67–73. PubMed PMC

Gross ER, Nithipatikom K, Hsu AK, Peart JN, Falck JR, Campbell WB, Gross GJ. Cytochrome P450 ω-hydroxylase inhibition reduces infarct size during reperfusion via the sarcolemmal KATP channel. J Mol Cell Cardiol. 2004;37:1245–1249. PubMed

Nithipatikom K, Endsley MP, Moore JM, Isbell MA, Falck JR, Campbell WB, Gross GJ. Effects of selective inhibition of cytochrome P-450 ω-hydroxylases and ischemic preconditioning in myocardial protection. Am J Physiol Heart Circ Physiol. 2006;290:H500–H505. PubMed

Sixty Years of Heart Research in the Institute of Physiology of the Czech Academy of Sciences

Inappropriate activation of the renin-angiotensin system improves cardiac tolerance to ischemia/reperfusion injury in rats with late angiotensin II-dependent hypertension

Epoxylipids and soluble epoxide hydrolase in heart diseases

Increased Endogenous Activity of the Renin-Angiotensin System Reduces Infarct Size in the Rats with Early Angiotensin II-dependent Hypertension which Survive the Acute Ischemia/Reperfusion Injury

Early Renal Vasodilator and Hypotensive Action of Epoxyeicosatrienoic Acid Analog (EET-A) and 20-HETE Receptor Blocker (AAA) in Spontaneously Hypertensive Rats

Epoxyeicosatrienoic Acid Analog and 20-HETE Antagonist Combination Prevent Hypertension Development in Spontaneously Hypertensive Rats

Epoxyeicosatrienoic acid analog EET-B attenuates post-myocardial infarction remodeling in spontaneously hypertensive rats

Epoxyeicosatrienoic Acid-Based Therapy Attenuates the Progression of Postischemic Heart Failure in Normotensive Sprague-Dawley but Not in Hypertensive Ren-2 Transgenic Rats

Infarct size-limiting effect of epoxyeicosatrienoic acid analog EET-B is mediated by hypoxia-inducible factor-1α via downregulation of prolyl hydroxylase 3

Two pharmacological epoxyeicosatrienoic acid-enhancing therapies are effectively antihypertensive and reduce the severity of ischemic arrhythmias in rats with angiotensin II-dependent hypertension

Combined Inhibition of Soluble Epoxide Hydrolase and Renin-Angiotensin System Exhibits Superior Renoprotection to Renin-Angiotensin System Blockade in 5/6 Nephrectomized Ren-2 Transgenic Hypertensive Rats with Established Chronic Kidney Disease

Epoxyeicosatrienoic acid analog attenuates the development of malignant hypertension, but does not reverse it once established: a study in Cyp1a1-Ren-2 transgenic rats

Inhibition of soluble epoxide hydrolase does not improve the course of congestive heart failure and the development of renal dysfunction in rats with volume overload induced by aorto-caval fistula

Different mechanisms of acute versus long-term antihypertensive effects of soluble epoxide hydrolase inhibition: studies in Cyp1a1-Ren-2 transgenic rats

Inhibition of soluble epoxide hydrolase is renoprotective in 5/6 nephrectomized Ren-2 transgenic hypertensive rats

Antihypertensive action of soluble epoxide hydrolase inhibition in Ren-2 transgenic rats is mediated by suppression of the intrarenal renin-angiotensin system

Antihypertensive and renoprotective actions of soluble epoxide hydrolase inhibition in ANG II-dependent malignant hypertension are abolished by pretreatment with L-NAME

Soluble epoxide hydrolase inhibition exhibits antihypertensive actions independently of nitric oxide in mice with renovascular hypertension